Share your videos with the world

Sign Up | Log In | Help  

   
 
Related Tags: abbott  health  heart  procedure  fda  coronary  artery  disease  food  drug  administration  multivu  7826651  fda  approval  boston  scientific  coronary  artery  disease  drug  research  science  health  multivu  7223456  ohiohealth  peripheral  artery  disease  blockages  drug  eluting  stent  balloon  angioplasty  coronary  multivu  60291  corindus  corpath  200  system  vascular  robotics  coronary  artery  stent  cardiology  surgery  technology  multivu  57343  promus  element  plus  stent  system  boston  scientific  fda  des  technology  coronary  artery  disease  ptcr  multivu  43510  oston  scientific  introduces  first  ipad  app  physicians  educate  patients  cardiovascular  diseases  multivu  43509  bioengineered  veins  humacyte  coronary  bypass  dialysis  cabg  av  graft  healthcare  multivu  48336  c  r  bard  inc  bard  lifestent  vascular  stent  resilient  trial  results  lesions  superficial  fem  artery 
Search // artery
Results 1-8 of 8 for ' artery ' (0 seconds)
Abbott announced today that the U.S. Food and Drug Administration has approved the company’s Absorb bioresorbable heart stent, making the first-of-its-kind medical device commercially available to treat people with coronary artery disease in the United States. Absorb is the only fully dissolving stent approved for the treatment of coronary artery disease, which affects 15 million people in the United States and remains a leading cause of death worldwide, despite decades of therapeutic advances. While stents are traditionally made of metal, Abbott’s Absorb stent is made of a naturally dissolving material, similar to dissolving sutures. Absorb disappears completely in approximately three years, after it has done its job of keeping a clogged artery open and promoting healing of the treated artery segment. By contrast, metal stents are permanent implants that restrict vessel motion for the life of the person treated. To view the multimedia release go to: http://www.multivu.com/players/English/7826651-abbott-fda-approval-stent/
Categories // Miscellaneous 
Added: 2231 days ago by MultiVuVideos
Runtime: 1m33s | Views: 507 | Comments: 0
Not yet rated
 

 

 

Boston Scientific (NYSE: BSX) has received U.S. Food and Drug Administration (FDA) approval for the SYNERGY™ Bioabsorbable Polymer Drug-Eluting Stent System (BP-DES) for the treatment of coronary artery disease. With this FDA approval, Boston Scientific will commence commercialization of the first and only BP-DES in the U.S. Notably, both the drug coating and the polymer – which modulates drug release – are fully absorbed shortly after drug elution is complete at three months. The SYNERGY Stent provides synchronized drug and polymer absorption. It is designed to enable more rapid and complete arterial healing, and to thereby reduce the risk of complications associated with long-term polymer exposure compared to currently-used drug-eluting stents (DES) with permanent polymers. To view the multimedia release go to: http://www.multivu.com/players/English/7223456-boston-scientific-fda-approval-synergy/
Categories // Science and Technology 
Added: 2507 days ago by MultiVuVideos
Runtime: 0m45s | Views: 474 | Comments: 2
Not yet rated
 

 

 

OhioHealth Riverside Methodist Hospital is now treating patients with peripheral artery disease (PAD) with the first drug-eluting stent to be used outside of the heart. Cook Medical’s Zilver PTX is a drug-coated stent that is used to reopen a long thigh artery, located above the knee (the femoropopliteal artery), narrowed or blocked due to PAD. This is the most common artery for PAD blockages. To view Multimedia News Release, go to http://www.multivu.com/mnr/60291-ohiohealth-riverside-hospital-zilver-ptx-drug-coated-stent-for-pad
Categories // Science and Technology 
Added: 3455 days ago by MultiVuVideos
Runtime: 2m3s | Views: 859 | Comments: 0
Not yet rated
 

 

 

Corindus Vascular Robotics, a leading developer of precision vascular robotics, today announced FDA 510(k) clearance has been granted for the CorPath 200 System to be used in percutaneous coronary interventions (PCI). The technology is now approved in the United States to assist interventional cardiologists in performing PCI, a procedure to restore blood flow to blocked arteries in patients with coronary artery disease (CAD). “We are pleased to have received clearance from the FDA for the world’s first system designed for robotic-assisted PCI procedures,” said David M. Handler, President and CEO of Corindus Vascular Robotics. “This is an important milestone for interventional cardiology as we take the next step in transforming the way these procedures are performed in the future. The CorPath System offers hospitals the opportunity to bring robotic-assisted technology benefits to their coronary patients and their physicians.” To view Multimedia News Release, go to http://www.multivu.com/mnr/57343-corindus-vascular-robotics-wins-fda-510k-clearance-for-corpath-200-system
Categories // Business  Science and Technology 
Added: 3673 days ago by MultiVuVideo
Runtime: 7m55s | Views: 2903 | Comments: 1
Not yet rated
 

 

 

Boston Scientific Corporation (NYSE:BSX) announces U.S. Food and Drug Administration (FDA) approval for the PROMUS Element™ Plus Everolimus-Eluting Platinum Chromium Coronary Stent System, the Company’s next-generation drug-eluting stent (DES) technology. The PROMUS Element Stent, designed to provide physicians improved DES performance in treating patients with coronary artery disease, is built on an innovative platinum chromium (PtCr) platform with the market-leading everolimus drug. The Company plans to begin marketing the product in the U.S. immediately. To view Multimedia News Release, go to http://www.multivu.com/mnr/43510-boston-scientific-fda-promus-element-plus-platinum-chromium-stent-system
Categories // Science and Technology 
Added: 3913 days ago by MultiVuVideos
Runtime: 2m30s | Views: 5159 | Comments: 0
Not yet rated
 

 

 

Boston Scientific Corporation (NYSE: BSX) introduces its CardioTeach™ iPad® app, an industry-first, free educational resource to help healthcare professionals better educate patients and caregivers about therapy options related to cardiovascular and peripheral diseases, specifically atrial and ventricular arrhythmias, coronary artery disease, heart failure, heart rhythm disorders and peripheral vascular disease. To view Multimedia News Release, go to http://www.multivu.com/mnr/43509-boston-scientific-cardioteach-ipad-app
Categories // News and Politics 
Added: 3945 days ago by MultiVuVideos
Runtime: 2m22s | Views: 5488 | Comments: 0
Not yet rated
 

 

 

The day when a surgeon can pull a new human vein “off the shelf” for use in life-saving vascular surgeries is now one step closer to reality. New research published in the current issue of the journal Science Translational Medicine demonstrates the efficacy of tissue-engineered vascular grafts (TEVGs) that are immediately available at the time of surgery and have decreased potential for infection, obstruction or clotting. The bioengineering method of producing veins reported in the newly-published research shows promise in both large and small diameter applications, such as for Coronary Artery Bypass Graft (CABG) surgery and for vascular access in hemodialysis. To view Multimedia News Release, go to http://multivu.prnewswire.com/mnr/humacyte/48336/
Categories // News and Politics 
Added: 4212 days ago by MultiVuVideo
Runtime: 0m31s | Views: 5094 | Comments: 0
Not yet rated
 

 

 

C. R. Bard, Inc. today announced the publication of RESILIENT trial results by Circulation: Cardiovascular Interventions showing the Bard LifeStent® Vascular Stent improved patency and reduced revascularization rates in patients with moderate-length lesions in the superficial femoral artery (SFA) and proximal popliteal artery compared to patients treated with percutaneous transluminal angioplasty (PTA). To view Multimedia News Release, go to http://multivu.prnewswire.com/mnr/bard/44623/
Categories // News and Politics 
Added: 4444 days ago by MultiVuVideo
Runtime: 4m15s | Views: 5203 | Comments: 0
Not yet rated
 

 

 

Page 1 of 1  |  Go to page   



About Us   |   Help  |   Advertise on ClipMoon   |   Terms of Use   |   Privacy Policy   |   Copyright   |   Contact   |   Link us   |   RSS 
Copyright © 2007-2022 ClipMoon.com. All rights reserved.